期刊
UROLOGIA INTERNATIONALIS
卷 95, 期 2, 页码 167-176出版社
KARGER
DOI: 10.1159/000371894
关键词
Urinary tract infection; Escherichia coli lysate; OM-89S; Nitrofurantoin; Immune response
资金
- Basilea
- Bayer
- Bionorica
- Cubist
- Daiichi Sankyo
- Galenus
- MerLion
- OM Pharma/Vifor
- Paratek
- Pierre Fabre
- Rempex Pharma
- Rosen Pharma
- Shionogi
- Zambon
Background: One strategy for managing recurrent uncomplicated urinary tract infections (UTIs) is prevention. This study tested OM-89S, a lyophilized lysate of 18 Escherichia coli strains manufactured using a modified lytic process. Methods: This was a randomized, double-blind trial in 451 female subjects with recurrent uncomplicated UTIs. Period 1 of the study tested 6 mg of OM-89S versus placebo (3 months), plus a 3-month observation. Period 2 of the study was a 3-month treatment period (each monthly cycle consisted of 6 mg of OM-89S daily for 10 days and placebo for 20 days, vs. 50 mg nitrofurantoin daily for 30 days), plus a 3-month observation. Results: There was no difference in the mean rate of UTI episodes between the OM-89S (0.66 +/- 0.93) and placebo groups (0.63 +/- 0.86; p = 0.95) in period 1. Similar findings were obtained for period 2. OM-89S was well-tolerated. Conclusions: Our results did not demonstrate a preventive effect of OM-89S compared to placebo. This may be due to the low number of UTIs that occurred during the study, the high number of protocol violations, and/or the modified manufacturing process used for OM-89S. (C) 2015 S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据